Hirofumi Ohashi

This paper identifies PA-001, a macrocyclic peptide that inhibits SARS-CoV-2 infection by targeting the S2 subunit's FPPR region, showing broad antiviral activity and efficacy in animal models and clinical trials.

This study identifies Oxy229, a compound that disrupts the NTCP-EGFR receptor complex, selectively inhibiting HBV and HDV entry without affecting NTCP or EGFR physiological functions.

The paper introduces a required concentration index to rank antiviral efficacy of HCV drug combinations and shows multidrug treatments enhance activity but reduce genotype-specific efficacy.